Skip to main content

Table 4 Subgroups analysis of ORR achievement

From: Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients

Parameters ORR (n = 75) Not ORR (n = 24) P value
Age (years) 58.27 ± 10.09 57.04 ± 11.05  
Gender Male (n/%) 68 (76.4) 21 (23.6) 0.654
HBV (n/%) 71 (75.5) 23 (24.5) 0.820
HCV (n/%) 1 (50.0) 1 (50.0) 0.390
Drink (n/%) 33 (76.7) 10 (23.3) 0.841
Cirrhosis (n/%) 41 (74.5) 14 (25.5) 0.753
Tumor distributiona    0.765
  > =20% (n/%) 38 (74.5) 13 (25.5)  
  < 20 (n/%) 37 (77.1) 11 (22.9)  
Number of nodules
 1 (n/%) 26 (86.7) 4 (13.3) 0.095
  > 1 (n/%) 49 (71.0) 20 (29.0)  
  < =3 (n/%) 45 (83.3) 9 (16.7) 0.054
  > 3 (n/%) 30 (66.7) 15 (33.3)  
Largest nodule size > 3 cm (n/%) 54 (78.3) 15 (21.7) 0.278
Largest nodule size > 5 cm (n/%) 33 (75.0) 11 (25.0) 0.875
Portal vein invasion (n/%) 19 (65.5) 10 (34.5) 0.126
 Main portal vein invasion (n/%) 3 (37.5) 5 (62.5) 0.173
 First branch invasion (n/%) 4 (50.0) 4 (50.0)  
 Second branch invasion (n/%) 10 (76.9) 3 (23.1)  
Hepatic vein invasion (n/%) 12 (70.6) 5 (29.4) 0.585
ECOG performance status    0.595
 0 (n/%) 52 (74.3) 18 (25.7)  
 1 (n/%) 23 (79.3) 6 (20.7)  
Child-pugh stage    0.419
 A (n/%) 68 (74.7) 23 (25.3)  
 B (n/%) 7 (87.5) 1 (12.5)  
BCLC stage    0.029
 A (n/%) 19 (79.2) 5 (20.8)  
 B (n/%) 31 (88.6) 4 (11.4)  
 C (n/%) 25 (62.5) 15 (37.5)  
AFP    0.432
 Abnormal (n/%) 40 (72.7) 15 (27.3)  
 Normal (n/%) 35 (79.5) 9 (20.5)  
Previous cTACE    0.089
 Yes (n/%) 26 (66.7) 13 (33.3)  
 No (n/%) 49 (81.7) 11 (18.3)  
Previous surgery    0.136
 Yes (n/%) 53 (80.3) 13 (19.7)  
 No (n/%) 22 (66.7) 11 (33.3)  
Previous systematic chemotherapy    0.820
 Yes (n/%) 4 (80.0) 1 (20.0)  
 No (n/%) 71 (75.5) 23 (24.5)  
Previous radiofrequency ablation    0.585
 Yes (n/%) 12 (70.6) 5 (29.4)  
 No (n/%) 63 (76.8) 19 (23.2)  
Previous targeted therapy (n/%)    0.562
 Yes (n/%) 1 (100.0) 0 (0.0)  
 No (n/%) 74 (75.5) 24 (24.5)  
Chemoembolization reagent    0.248
 Adriamycin (n/%) 4 (100.0) 0 (0.0)  
 Epirubicin (n/%) 71 (74.7) 24 (25.3)  
  1. Data was presented as count (%) or mean ± standard deviation
  2. Comparison between groups was determined by t test or Chi-square test. P < 0.05 was considered significant. aTumor distribution: percentage of tumor in the whole liver
  3. HBV Hepatic b virus, HCV Hepatic c virus, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP Alpha fetal protein, cTACE Conventional transarterial chemo-embolization